TrialLancet (London, England)2023

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.

Martina Schneider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.